GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
NCT03751761
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
58
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Gastric Cancer
Interventions
DRUG:
durvalumab, tremelimumab, paclitaxel
Sponsor
Asan Medical Center
Collaborators
[object Object]
[object Object]